Benjamin Garmezy
@BGarmezy
Followers
387
Following
233
Media
22
Statuses
228
Associate Director of Genitourinary Research at Sarah Cannon Research Institute. Practicing at SCRI Oncology Partners in Nashville, TN. Views are my own.
Nashville, TN
Joined May 2020
This is great news for our patients, HLD-0915 and the AR RIPTAC tech will continue development with a strong team @BGarmezy @AarmstrongDuke @charlesryanmd @DCockrellMD
Big Pharma movement following promising early phase 1/2 data from a trial led by our own @OncHahn @MDAndersonNews in men with progressing mCRPC. @PCFnews J&J buys into Halda's cell death tech with $3B acquisition, beefing up prostate cancer pipeline
0
4
26
Agent797, new iNKT therapy, has a dramatic impact for some patients. Those who received with pd1 (post prior IO) had a median OS of ~2 years! A durable remission of three years (and going) in a germ cell patient! Was an honor to present at #SITC25. @SarahCannonDocs @SCRIOncology
At #SITC25, @MiNK_iNKT #agenT797 data show what’s possible when science meets persistence — durable remissions (2+ yrs), immune reactivation, & favorable safety. Grateful to our patients & team. 🔗 https://t.co/li0DCRrM6m | Poster: https://t.co/6oq4Yd0Q7N. Thank you @BGarmezy for
0
1
6
@SCRIOncology was honored to co-host the @AmericanCancer ACS gala in Nashville. Amazing fundraising effort benefitting patients facing cancer. @DavidRSpigel
@MLJohnsonMD2
@MeredithMcKean
@ErikaHamilton9
@BGarmezy
@MeredithPelster
@SPremji7866
@SarahCannonDocs
0
5
8
Thank you to @nabiladra! And follow @OncologyDecoded
In this episode of Oncology Decoded, Dr. Bupathi, Dr. Garmezy, and Dr. Adra discuss the best ways to diagnose and treat #TesticularCancer. Proud to see physicians in The Network sharing knowledge that will improve #CancerTreatment! https://t.co/zTHCTY3ej8
#TumorMarkers
0
0
6
Honored to represent @ASCO and @SarahCannonDocs at the JSCO 2025 conference in Tokyo. We had an amazing conversation about ctDNA in perioperative oncology. I look forward to even more data coming at #ESMO25 #esmo2025
2
1
19
Now it’s @MikeLattanzi’s turn! More @SarahCannonDocs representation at @GUconference #WORLDGU25! @TexasOncology
0
0
7
More SCRI representation at @GUconference #WORLDGU25! @jeffyoriomd part of an all star panel discussing mrd and better disease monitoring in gu cancers. @SarahCannonDocs @TexasOncology
0
2
12
Proud of @mkbupathi chairing a session on variant histology @GUconference #worldgu25 @SarahCannonDocs @TheUSONetwork He represents SCRI well!
1
2
12
@UroCancerMD showing us the evolving landscape on NMIBC. OncologyDecoded will attempt to demystify what we need to know as oncologists in the community! @GUconference #WorldGU2 @BGarmezy @mkbupathi
0
1
2
🚨 Countdown: 5 days to #WorldGU25! This isn’t your typical conference—2 days of cutting-edge education, 60+ renowned faculty, 11.75 CE credits, and the unmatched atmosphere of the @countrymusichof in Nashville, TN. Join the leaders shaping GU cancer care, chaired by
0
5
16
Coming soon: Oncology Decoded at @GUconference! Stay tuned from some updates and interviews from Nashville TN with @BGarmezy and @mkbupathi.
0
2
3
OUT NOW: A discussion/pod on toxicity management with Enfortumab vedotin and Pembrolizumab in advanced urothelial carcinoma. I hope it’s helpful. I was honored to work with @tompowles1 and Maria Lapuente! https://t.co/XPpoBGmJuR
@SCRIOncology @SarahCannonDocs @TheUSONetwork
link.springer.com
Oncology and Therapy - In the EV-302/KEYNOTE-A39 trial (NCT04223856), enfortumab vedotin + pembrolizumab (EV + P) became the first treatment in decades to demonstrate...
0
4
9
🧬ctDNA is reshaping bladder cancer care. NIAGARA, TOMBOLA, and IMvigor trials show how it can guide treatment, predict recurrence, and personalize adjuvant therapy to support more precise decisions. Learn more from @BGarmezy & @Mkbupathi: https://t.co/o3vALjguCK
0
1
1
Follow @OncologyDecoded for more and excited to discuss the exciting treatments that are in development for #prostatecancer at @GUconference!
Excited to partner with World GU to help translate all of the new exciting data to help you in clinic tomorrow! Also register for World GU where our own @BGarmezy and many others will be speaking on the latest updates in #guonc #prostatecancer #bladdercancer and #kidneycancer
0
0
7
Excited to partner with World GU to help translate all of the new exciting data to help you in clinic tomorrow! Also register for World GU where our own @BGarmezy and many others will be speaking on the latest updates in #guonc #prostatecancer #bladdercancer and #kidneycancer
0
4
6
iNKT Cells at the Interplay Between Innate and Adaptive Immune Responses - Hung Trinh @BGarmezy @jbuell01 @ODayMD
https://t.co/CgHvZNe8l9
#OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #iNKTCells #SalvageTherapy #GermCellTumor #TCells
0
3
7
Promising development as we continue to push cell therapy into solid tumors!
Dr. Benjamin Garmezy et al. published in Oncogene: “MiNK Therapeutics’ allogeneic iNKT cell therapy, agenT-797, continues to gain recognition as a promising approach in solid tumors."
0
0
4
Dr. Benjamin Garmezy et al. published in Oncogene: “MiNK Therapeutics’ allogeneic iNKT cell therapy, agenT-797, continues to gain recognition as a promising approach in solid tumors."
oncodaily.com
A Growing Body of Clinical Data Showing the Potential of iNKT Cell Therapy - MiNK Therapeutics / agenT-797, allogeneic iNKT cell therapy, Benjamin Garmezy,
0
2
16
📌New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor A groundbreaking case study published in Oncogene (2025) demonstrates the first documented complete remission of a heavily pre-treated metastatic germ cell tumor using
1
1
11